MBio is developing a family of point-of-care, multiplex tests for host-response biomarkers in blood. Host-response biomarkers can be measured early in acute infection. Research indicates that certain combinations of these biomarkers may be prognostic for cytokine storm and associated bad outcomes in COVID-19 and sepsis. Our panels will provide rapid results that may give insights about immune response, help inform treatment decisions and direct resource allocation in a crisis.
Affects 30 million people, 6 million deaths annually.
Sepsis can progress rapidly and can be fatal if not treated quickly. Each hour of delay in giving antibiotics increases risk of death by 7%.
High cost, morbidity and mortality
Costs $27 billion in the U.S.
Clinical Utility of MBio Host-Response Panels
|Diagnosis: Differentiate between infectious vs. non-infectious etiology||Determine the need for broad spectrum antibiotics vs. COVID-19 intervention vs. non-infectious intervention|
|Staging: Where the patient is on the disease continuum: low-risk to cytokine storm?||Guide aggressiveness of treatment and resource allocation for optimal outcomes at lower cost|
|Monitoring: Assess response to treatment||Can antibiotics be de-escalated? Should treatment be more aggressive?|
Products are for research use only or under development and not available for sale.